Please provide your email address to receive an email when new articles are posted on . A low dose of sumatriptan provided significantly higher 2-hour pain freedom and 2-hour pain relief vs. placebo, ...
Sumatriptan Succinate Injection is indicated for 1) the acute treatment of migraine attacks with or without aura and 2) the acute treatment of cluster headache episodes. Sumatriptan Succinate ...
Teva and Antares Pharma announced the launch of Sumatriptan Succinate Injection, the generic version of GlaxoSmithKline's Imitrex Injection. Imitrex Injection is indicated in adults for the acute ...
SCHAUMBURG, Ill., Aug. 2 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced two FDA approvals -- sumatriptan succinate injection and ...
Sumatriptan (as succinate) 4mg/0.5mL, 6mg/0.5mL; for SC inj. Imitrex Injection is supplied as a clear, colorless to pale yellow, sterile, nonpyrogenic solution as either prefilled syringe and/or ...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL For Subcutaneous Use, a ...
The Food and Drug Administration (FDA) has approved a creation of the Imitrex Injection that enables patients to consume a 4mg dosage, named as the Imitrex STAT dose System ® used to treat severe ...
SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders ...
Dr. Reddy's Laboratories (NYSE: RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination ...
MUMBAI, Feb 17 (Reuters) - Drug firm Wockhardt Ltd on Tuesday said it will be launching Sumatriptan injections in the U.S. following following final approval from the U.S. Food & Drug Administration.
SAN DIEGO and HAMBURG, Germany, Jan. 6, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") today announced that the Federal Institute for ...
Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results